Accretion Nutraveda Ltd vs Aptus Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 267.5 as of 29 Apr 15:30 . The P/E Ratio of Accretion Nutraveda Ltd is 0 as of March 2023 .The P/E Ratio of Aptus Pharma Ltd is 0 as of March 2023 . The Market Cap of Accretion Nutraveda Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Aptus Pharma Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Accretion Nutraveda Ltd is 0 % as of March 2023 .The Dividend Payout of Aptus Pharma Ltd is 0 % as of March 2023.

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

FAQs for the comparison of Accretion Nutraveda Ltd and Aptus Pharma Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Aptus Pharma Ltd?

Market cap of Accretion Nutraveda Ltd is 193 Cr while Market cap of Aptus Pharma Ltd is 277 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Aptus Pharma Ltd?

The stock performance of Accretion Nutraveda Ltd and Aptus Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Aptus Pharma Ltd?

As of May 3, 2026, the Accretion Nutraveda Ltd stock price is INR ₹267.5. On the other hand, Aptus Pharma Ltd stock price is INR ₹405.0.

How do dividend payouts of Accretion Nutraveda Ltd and Aptus Pharma Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Aptus Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.